“We're very confident in that and fiscal year-to-date, as we mentioned in the script, we're right at that level.”

In context

“together, two conclusions. One, the headwinds that we're calling out are temporary in nature. So first of all, the inventory reduction, which is a point on the top-line, we expect that to be a single event, not a continued phenomena to observe. It was mainly driven by Personal Healthcare, because the supply situation is stabilizing after a softer season, so retailers don't need to hold safety stock. And the headwinds in China on SK-II and in the Middle East will ease over time and eventually annualize over the coming quarters. That does not mean that we will ignore any of the headwinds. We are fully focused on accelerating growth in China on SK-II and driving sustainable growth in Asia and Middle East markets, but it explains that we can hold our organic sales growth guidance at 4% to 5%. We're very confident in that and fiscal year-to-date, as we mentioned in the script, we're right at that level. Last point on that topic, we remain fully invested, and the gross margin progress the team has made is actually enabling us to continue to double down on investments, drive market growth and drive our own consumption and share within that. Specifically on China to the second part of your question, Lauren, I think it's a good way to look at China excluding SK-II, as you suggest. We are making sequential progress. The share in the most recent read is flat, and our shipments or our organic sales in China are improving quarter-over-quarter. If we look at quarter two, our organic sales excluding SK-II in China were down 10%. In the most recent quarter, they were down 3%. So we're making progress. The market is not yet recovering, but we see the trajectory going in the right direction. We have”